Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $3.1 million.

  • Allogene Therapeutics' Depreciation & Amortization (CF) fell 343.0% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 971.62%. This contributed to the annual value of $13.6 million for FY2024, which is 395.07% down from last year.
  • Allogene Therapeutics' Depreciation & Amortization (CF) amounted to $3.1 million in Q3 2025, which was down 343.0% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Depreciation & Amortization (CF) ranged from a high of $4.2 million in Q4 2021 and a low of $1.9 million during Q1 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $3.3 million, with a median of $3.5 million in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 13004.34% in 2021, then crashed by 2767.56% in 2022.
  • Allogene Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $4.2 million in 2021, then dropped by 27.68% to $3.1 million in 2022, then grew by 13.36% to $3.5 million in 2023, then decreased by 7.04% to $3.2 million in 2024, then fell by 4.21% to $3.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $3.1 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.1 million for Q1 2025.